gain of function mutation
Summary
A gain-of-function mutation causes a gene product to acquire a new or enhanced activity, rather than losing its normal function. These mutations are typically dominant and can lead to disease through overactive signaling, toxic protein accumulation, or novel protein interactions.
Detail
Gain-of-function (GOF) mutations alter a gene product such that it gains new molecular function, is expressed at inappropriately high levels, or becomes constitutively active (always 'on'), independent of normal regulatory control. This contrasts with loss-of-function (LOF) mutations, which reduce or eliminate protein activity and are typically recessive (require both alleles affected) unless haploinsufficiency occurs. GOF mutations are usually dominant because even one mutant allele can produce the abnormal, overactive protein alongside the normal one, overriding normal cellular regulation.
Mechanisms include: (1) constitutive activation of a receptor or enzyme (e.g., RAS, RET, FGFR3 mutations causing continuous downstream signaling without ligand binding), (2) increased gene dosage/expression (e.g., gene amplification), (3) acquisition of a novel toxic function (e.g., polyglutamine expansion in Huntington's disease creating aggregation-prone protein), or (4) dominant-negative effects, in which mutant protein actively interferes with the function of the wild-type protein (a related but distinct concept).
Clinically significant examples: - RET proto-oncogene GOF mutations cause multiple endocrine neoplasia type 2 (MEN2A/2B), leading to constitutively active RET tyrosine kinase and medullary thyroid carcinoma, pheochromocytoma. - FGFR3 GOF mutations cause achondroplasia (constitutive receptor activation inhibits chondrocyte proliferation) and also seen in some bladder cancers. - RAS oncogenes (KRAS, HRAS, NRAS) GOF mutations lock the GTPase in an active GTP-bound state, promoting unchecked cell proliferation in many cancers. - Huntington's disease: CAG trinucleotide repeat expansion produces a mutant huntingtin protein with toxic gain of function (aggregation, neuronal toxicity), distinct from typical LOF disorders. - JAK2 V617F mutation causes constitutive JAK-STAT signaling in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis). - CFTR gating mutations can sometimes be considered as altering function, though most CF mutations are LOF; contrast highlights distinction.
Understanding GOF vs LOF is essential for USMLE questions about oncogenes (typically GOF, dominant) versus tumor suppressor genes (typically LOF, recessive, 'two-hit hypothesis'). It also matters for understanding inheritance patterns (autosomal dominant diseases often due to GOF or dominant-negative mutations) and for therapeutic strategies (e.g., targeted kinase inhibitors for GOF oncogenic mutations like imatinib for BCR-ABL, vemurafenib for BRAF V600E).
Sources
- Robbins and Cotran Pathologic Basis of Disease
- First Aid for the USMLE Step 1
- Molecular Biology of the Cell (Alberts et al.)
- Thompson & Thompson Genetics in Medicine
Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.